Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report released on Wednesday. The brokerage issued an overweight rating and a $25.00 target price on the stock.

A number of other research firms also recently commented on ZVRA. Roth Mkm boosted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, JMP Securities started coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $21.57.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $8.53 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The firm has a market capitalization of $455.30 million, a P/E ratio of -4.33 and a beta of 2.01. The company’s fifty day moving average is $8.78 and its two-hundred day moving average is $7.58.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the business posted ($0.40) earnings per share. Analysts forecast that Zevra Therapeutics will post -1.96 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Several large investors have recently modified their holdings of ZVRA. International Assets Investment Management LLC lifted its holdings in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares during the last quarter. Hunter Associates Investment Management LLC acquired a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at approximately $92,000. XTX Topco Ltd bought a new position in Zevra Therapeutics during the third quarter worth $94,000. Intech Investment Management LLC bought a new stake in Zevra Therapeutics during the third quarter valued at $95,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Zevra Therapeutics during the third quarter worth $105,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.